Juno Therapeutics signs licensing agreements with Lilly, OncoTracker and the Hutch
Juno Therapeutics announced three license agreements to advance its program in multiple myeloma using gamma secretase inhibitors in combination with BCMA-directed CAR T cells. Gamma secretase is an enzyme that cleaves a set of transmembrane proteins, including BCMA. December 06, 2017